北京凯因科技股份有限公司2025年度业绩预告公告

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between 26 million and 38 million yuan, representing a decrease of 10.43692 million to 11.63692 million yuan compared to the previous year, which is a year-on-year decline of 73.31% to 81.74% [1] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 20 million and 30 million yuan, a decrease of 10.69831 million to 11.69831 million yuan compared to the previous year, reflecting a year-on-year decline of 78.10% to 85.40% [1] - The previous year's net profit attributable to shareholders of the parent company was 142.3692 million yuan, with a total profit of 176.8329 million yuan for 2024 [1][2] Group 2 - The primary reason for the significant change in performance is the company's decision to fully provision for asset impairment related to the withdrawal of a drug registration application for a new hepatitis indication, which was based on the latest review recommendations from the National Medical Products Administration [3] - Excluding the impact of this asset impairment, the company's net profit for 2025 is expected to be roughly in line with the previous year, indicating stable development of its core business [3]